Huang SM, Wen DG. Letter to the Editor: Hepatic transcriptome and metabolome analysis of Jiangtang Tiaozhi formula. World J Diabetes 2026; 17(6): 117759 [DOI: 10.4239/wjd.117759]
Corresponding Author of This Article
Di-Guang Wen, PhD, Academic Fellow, Professor, Department of Endocrinology, Yuyao People's Hospital, No. 800 Chengdong Road, Yuyao 315400, Zhejiang Province, China. 2018110626@stu.cqmu.edu.cn
Research Domain of This Article
Cell Biology
Article-Type of This Article
letter
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Huang SM, Wen DG. Letter to the Editor: Hepatic transcriptome and metabolome analysis of Jiangtang Tiaozhi formula. World J Diabetes 2026; 17(6): 117759 [DOI: 10.4239/wjd.117759]
World J Diabetes. Jun 15, 2026; 17(6): 117759 Published online Jun 15, 2026. doi: 10.4239/wjd.117759
Letter to the Editor: Hepatic transcriptome and metabolome analysis of Jiangtang Tiaozhi formula
Shu-Meng Huang, Di-Guang Wen
Shu-Meng Huang, Di-Guang Wen, Department of Endocrinology, Yuyao People's Hospital, Yuyao 315400, Zhejiang Province, China
Author contributions: Huang SM drafted the manuscript; Wen DG designed the study, supervised the project, and critically revised the manuscript; both authors read and approved the final version of the manuscript.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Corresponding author: Di-Guang Wen, PhD, Academic Fellow, Professor, Department of Endocrinology, Yuyao People's Hospital, No. 800 Chengdong Road, Yuyao 315400, Zhejiang Province, China. 2018110626@stu.cqmu.edu.cn
Received: December 15, 2025 Revised: January 15, 2026 Accepted: January 26, 2026 Published online: June 15, 2026 Processing time: 178 Days and 16.6 Hours
Abstract
Jiangtang Tiaozhi formula (JTTZF) has been widely used in the management of glycolipid metabolic disorders, yet its underlying molecular mechanisms remain incompletely understood. Tian et al recently published a study in the World Journal of Diabetes, which reported a comprehensive hepatic transcriptomic and metabolomic analysis that provides important insights into the regulatory effects of JTTZF on glucose and lipid homeostasis. This multi-omics strategy offers a valuable systems-level perspective on the pharmacological actions of this traditional Chinese medicine formulation. In this commentary, we highlight the strengths of the study and discuss several aspects that warrant further investigation to enhance mechanistic depth and translational relevance. These include dose-response relationships, cellular heterogeneity, causal validation of key pathways, identification of active constituents, and long-term safety evaluation. We also emphasize the potential role of host-related factors, such as immune regulation and gut microbiota-associated metabolic interactions, in influencing therapeutic responsiveness.
Core Tip: This commentary discusses a recent hepatic transcriptomic and metabolomic study that elucidates the regulatory effects of Jiangtang Tiaozhi formula on glycolipid metabolism. We emphasize key strengths of the multi-omics strategy and highlight critical issues that warrant further investigation, including dose-response relationships, cellular resolution, mechanistic causality, active constituent identification, and long-term safety evaluation. By integrating systems biology and translational perspectives, this work underscores the potential of traditional Chinese medicine-based therapies to advance precision medicine approaches for metabolic disorders.
